Former Chief Scientific Officer · aTYR PHARMA INC (ATYR)

David King

A named executive officer of aTYR PHARMA in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$717,312

Salary $304,583Stock awards $0

FY2017: $549,359

3rd of 4 named executive officers at aTYR Pharma by FY2018 total.

4 named officers on file for aTYR PHARMA, FY2018

David King’s pay file — $29

  • 2 fiscal years of pay, line by line
  • ATYR’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how aTYR PHARMA’s whole pay program stands against its peers

  • aTYR PHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ATYR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 28, 2019 (DEF 14A).

Free

Get David King’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

David King compensation by year

aTYR PHARMA Summary Compensation Table · all 2 fiscal years held
In US dollars, as aTYR PHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$300,000$304,583
Bonus$0$0
Stock awards$0$0
Option awards$173,979$390,000
Non-equity incentive$68,250$0
Pension and deferred compensation$0$0
All other$7,130$22,729
Total$549,359$717,312

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: aTYR PHARMA INC DEF 14A filed March 28, 2019, accession 0001564590-19-009824, and prior-year filings.

How this page was built: the aTYR PHARMA INC filed document, accession 0001564590-19-009824. Every figure is read from that document and cited to the page and table it appears in. Filed March 28, 2019.

$549K
$717K
FY17
FY18
SalaryNon-equity incentiveOption awardsAll other

aTYR PHARMA’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Sanjay ShuklaPresident and CEO$1,380,465
Ashraf AmanullahFormer Senior Vice President, Biologics, Development and Manufacturing$772,470
David King · this pageFormer Chief Scientific Officer$717,312
Jill BroadfootChief Financial Officer$334,123

The full aTYR PHARMA compensation record

free company brief

This page is one person within aTYR PHARMA's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the aTYR PHARMA proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are aTYR PHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David King's compensation dossier · One-time report. No refunds.